Scarica l'app Stockscreener
276.40
2.83%
7.60
Dopo l'orario di chiusura:
276.40
Precedente Chiudi:
$268.80
Aprire:
$272.46
Volume 24 ore:
803.63K
Relative Volume:
0.81
Capitalizzazione di mercato:
$6.91B
Reddito:
$1.77M
Utile/perdita netta:
$-123.74M
Rapporto P/E:
-30.14
EPS:
-9.17
Flusso di cassa netto:
$-95.21M
1 W Prestazione:
+2.00%
1M Prestazione:
+48.27%
6M Prestazione:
+523.93%
1 anno Prestazione:
+293.84%
Intervallo 1D:
$270.55
$282.99
Intervallo di 1 settimana:
$251.00
$282.99
Portata 52W:
$26.70
$282.99
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Confronta PRAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
276.40 | 6.72B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Has Praxis Precision Medicines Rally Gone Too Far or Is the Market Still Missing Something - Yahoo Finance
Oppenheimer Raises Price Target for Praxis Precision Medicine (P - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month HighWhat's Next? - MarketBeat
Praxis Precision Medicines stock hits 52-week high at 279.0 USD - Investing.com
Oppenheimer Adjusts Praxis Precision Medicines PT to $750 From $250, Maintains Outperform Rating - marketscreener.com
Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer - Investing.com UK
Best Pharmaceutical Stocks To Watch TodayDecember 5th - MarketBeat
(PRAX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Praxis Precision Medicines Plans New Drug Application - The Globe and Mail
Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 - Yahoo Finance
Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating - marketscreener.com
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance
Praxis Precision Medicines updates clinical trial design and regulatory plans - Investing.com
Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - MSN
Praxis Precision Medicines Confirms FDA Filing Path for New Drug Application of Relutrigine in Early 2026 - Quiver Quantitative
TD Cowen lifts Praxis Precision Medicines Inc. (PRAX) price target amid NDA for essential tremor treatment - MSN
Praxis Precision Medicines Announces Plans to File an NDA - GlobeNewswire
TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment - Insider Monkey
HighVista Strategies LLC Buys 28,002 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis a new buy at BTIG as biotech is a top pick for 2026 - MSN
Stempoint Capital LP Takes $1.36 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Maven Securities LTD Buys Shares of 5,000 Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Says FDA Agrees to Proposed Changes to Embrave3 Trial Design - marketscreener.com
PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus
Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative
Praxis Precision Medicines announces alignment with FDA - marketscreener.com
PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus
Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan
Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Eastern Progress
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive - ts2.tech
Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Shares Bought by Swiss National Bank - MarketBeat
Praxis Precision Medicine (PRAX): Guggenheim Raises Price Target to $760 | PRAX Stock News - GuruFocus
Praxis Precision Medicines Inc. (PRAX) secures analyst confidence after key FDA and trial wins - MSN
Needham raises Praxis Precision Medicines stock price target on improved data - Investing.com Australia
Praxis Precision Medicines, Inc. $PRAX Stock Holdings Boosted by B Group Inc. - MarketBeat
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins - Insider Monkey
BTIG maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
PRAX Stock Surge: Rally or Risk? - StocksToTrade
Praxis Precision Medicines reports clinical updates on epilepsy drug candidates - Investing.com Nigeria
Praxis Precision Medicines Shares RADIANT Study Results - TipRanks
TD Cowen Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $353.00 - MarketBeat
TD Cowen Raises Price Target for PRAX to $353, Maintains Buy Rat - GuruFocus
Praxis Precision Medicines stock price target raised to $353 from $251 at TD Cowen - Investing.com Nigeria
Truist Securities Raises Price Target for PRAX to $500 | PRAX St - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Given New $500.00 Price Target at Truist Financial - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 9.2% Following Analyst Upgrade - MarketBeat
Truist Securities raises Praxis Precision Medicines stock price target to $500 - Investing.com Nigeria
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):